New triple‑target drug shows huge weight loss but safety still unclear

Posted by amber464 in Weight Loss & Metabolic - 1 points, 0 comments.

https://time.com/article/2026/05/21/eli-lilly-new-weight-loss-drug/

I just read the Time piece on Eli Lilly’s next‑gen candidate retatrutide, which hits three hormones instead of one. The early trial data show participants losing up to 30 % of body weight in a few months, far beyond what we see with standard GLP‑1s.

For me the hype feels a bit premature. The article glosses over the uptick in gastrointestinal complaints and the small but notable drop in lean mass that some subjects reported. In my own low‑dose semaglutide runs I’ve seen a steady drop in step count and occasional loss of muscle unless I crank up protein and resistance work. I’m curious if the added GIP and glucagon activity will make those side effects worse or actually help preserve muscle. Also, the study cohort was mostly people with BMI > 35, so we don’t know how it’ll work for folks like me in the 30‑35 range.

Has anyone here tracked lean‑mass changes on multi‑agonist trials, or do you think the extra hormone pathways will just amplify the same gut issues we already see with GLP‑1s?

Community discussion - research and educational context only. Not medical advice.